CClinicalTrials.gg
CompletedNCT04867122Updated May 8, 2026

Problem-Solving Therapy for Cancer Caregivers in Outpatient Palliative Care

An interventional study of Problem-Solving Therapy and Attention-matched Control in Depression, Anxiety, Palliative Care and Caregivers, sponsored by Washington University School of Medicine. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
532
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a randomized clinical trial of a problem-solving therapy intervention for family caregivers of individuals with cancer receiving outpatient palliative care.

Read the detailed description

This study is a randomized clinical trial of a problem-solving therapy intervention for family caregivers of individuals with cancer receiving outpatient palliative care. Study participants will be randomized to receive either a three-session problem-solving therapy intervention in addition to usual care or three sessions of attention-matched control in addition to usual care.

02

Conditions studied

  • Depression, Anxiety
  • Palliative Care
  • Caregivers
  • Cancer
03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 532 is above the median of 84 across 6,720 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,765 studies on the registry; 271 are open to participants now.

Of its 324 completed or terminated interventional studies of FDA-regulated products, 212 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Must be 18 years of age or older
  • Must serve as the unpaid family caregiver of a patient with cancer receiving outpatient palliative care from one of the participating clinical sites. As is common in caregiving research, we will define "family caregiver" as anyone substantially involved in a patient's care on an unpaid basis; a legal or biological relationship will not be required
  • Must consent to participate

Inclusion Criteria for Non-Family Caregiver Stakeholders

  • Must be 18 years of age or older
  • Must be employed by or affiliated with the healthcare system housing one of the participating clinical sites.
  • Must consent to participate.

Exclusion criteria

Exclusion Criteria for Family Caregivers (FCGs)

  • Younger than 18 years of age
  • Paid caregiver

Exclusion Criteria for Non-Family Caregiver Stakeholders

  • Younger than 18 years of age
  • Not employed by or affiliated with the healthcare system housing one of the participating clinical sites.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
532 participants (actual)

Study arms

  • Placebo comparator
    Attention Control

    Family caregivers in the attention control study arm will receive three sessions of attention-matched control in addition to the services and support provided as part of usual outpatient palliative care. Attention-matched control will consist of three "friendly visits" with a trained research staff person.

    Other: Attention-matched Control

  • Experimental
    Problem Solving Therapy Intervention

    Family caregivers in the intervention study arm will participate in three problem-solving therapy sessions with a trained interventionist in addition to receiving the services and support provided as part of usual outpatient palliative care.

    Behavioral: Problem-Solving Therapy

  • Other
    In-Depth Interviews for non-FCG Stakeholders

    Each year of the project, the investigators will recruit 6 key stakeholders to participate in individual interviews focused on potential barriers and facilitators to adoption of the PST intervention into clinical practice for a total of 30 unique stakeholders who will be interviewed over the duration of this 5-year study.

    Other: In-depth interviews

Interventions

  • BehavioralProblem-Solving Therapy

    Over an approximately 3-week period, family caregivers randomized to the intervention study arm will learn and apply a problem-solving approach based on the ADAPT model, which encourages participants to follow five steps when solving caregiving problems: 1) focus on adopting a positive attitude to problem solving, 2) define the problem and set goals, 3) generate a list of alternative solutions to the problem, 4) predict consequences of the alternative solutions, and 5) try implementing the most promising solution from among the list of alternatives. The intervention will be delivered by a trained interventionist over the course of three structured sessions via telephone or videoconferencing technology, depending on the FCG's preference. Session content will be summarized in an intervention manual, which we will provide to all intervention participants. Sessions will last approximately 45-60 minutes.

  • OtherAttention-matched Control

    Over an approximately 3-week period, family caregivers randomized to the attention control study arm will participate in informal conversations ("friendly visits") with a trained member of the research team.

  • OtherIn-depth interviews

    The 30 key stakeholders interviews will discuss how the PST intervention fits into existing clinical practice and institutional values, what might incentivize adoption of the PST intervention, and how the intervention compares to alternative existing or proposed programs.

06

What researchers measure

Primary outcomes

  1. Change in anxiety as measured by the PROMIS Short Form v1.0 - Anxiety 8a

    Family caregivers indicate the frequency with which they experience eight different symptoms of anxiety (8 items); higher scores reflect higher anxiety severity.

    Time frame: At the time of enrollment, Week 4, and 30-day follow-up

  2. Change in symptoms of depression as measured by the PROMIS Short Form v1.0 - Depression 8a

    Family caregivers indicate the frequency with which they experience eight different symptoms of depression (8 items); higher scores reflect higher depression severity

    Time frame: At the time of enrollment, Week 4, and 30-day follow-up

Secondary outcomes

  1. Change in positive aspects of caregiving as measured by Positive Aspects of Caregiving Scale - Short Form (S-PAC; 7 items)

    * Family caregivers indicate good things that they experience as a caregiver with seven different statements. The caregivers answer with 1=I disagree with this statement a lot; 2=I disagree with this statement a little; 3=I neither agree nor disagree with this statement; 4=I agree with this statement a little; or 5=I agree with this statement a lot. * Higher scores indicate a more positive caregiving experience

    Time frame: At the time of enrollment, Week 4, and 30-day follow-up

07

Study locations

3 sites
  • University of Missouri
    Columbia, Missouri 65211, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • University of Pennslyvania
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Study documents

  • Informed consent form · Apr 3, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04867122
Lead sponsor
Washington University School of Medicine
Collaborators
University of Pennsylvania, National Cancer Institute (NCI), University of Missouri-Columbia
Responsible party
Sponsor
First posted
Apr 30, 2021
Start date
Jan 24, 2022
Primary completion
Dec 1, 2025
Completion
Dec 1, 2025
Last update
May 8, 2026

Study contacts

Karla Washington, Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion